about
Harnessing immunosurveillance: current developments and future directions in cancer immunotherapyImmunotherapy for colorectal cancerMechanistic insights into the oncolytic activity of vesicular stomatitis virus in cancer immunotherapyTherapeutic cancer vaccines and combination immunotherapies involving vaccinationVaxvec: The first web-based recombinant vaccine vector database and its data analysisAttenuated Listeria monocytogenes: a powerful and versatile vector for the future of tumor immunotherapy.Dendritic-cell-based therapeutic cancer vaccinesTroVax in colorectal cancerDendritic cell-specific delivery of Flt3L by coronavirus vectors secures induction of therapeutic antitumor immunityGene Therapies for Cancer: Strategies, Challenges and Successes.Immunotherapeutic approaches to ovarian cancer treatment.Therapeutic effect of intratumoral administration of DCs with conditional expression of combination of different cytokines.Trial watch: Naked and vectored DNA-based anticancer vaccinesDevelopment of a Minor Histocompatibility Antigen Vaccine Regimen in the Canine Model of Hematopoietic Cell Transplantation.Anti-CD73 in cancer immunotherapy: awakening new opportunities.Trial watch: DNA vaccines for cancer therapy.A randomized phase II study of immunization with dendritic cells modified with poxvectors encoding CEA and MUC1 compared with the same poxvectors plus GM-CSF for resected metastatic colorectal cancer.Chemokine-based immunotherapy: delivery systems and combination therapies.Clinical applications of attenuated MVA poxvirus strain.Environmental risk assessment of clinical trials involving modified vaccinia virus Ankara (MVA)-based vectors.Immunotherapy in prostate cancer: review of the current evidence.Peptide-based vaccination and induction of CD8+ T-cell responses against tumor antigens in breast cancer.Impact of the immune system and immunotherapy in colorectal cancer.Replicating poxviruses for human cancer therapy.Microneedles: an innovative platform for gene delivery.Engineered Materials for Cancer Immunotherapy.Cancer vaccines in colon and rectal cancer over the last decade: lessons learned and future directions.Advances in immunotherapy for the treatment of glioblastoma.Engaging Natural Killer T Cells as 'Universal Helpers' for Vaccination.Semliki Forest virus biodistribution in tumor-free and 4T1 mammary tumor-bearing mice: a comparison of transgene delivery by recombinant virus particles and naked RNA replicon.Modified Vaccinia virus Ankara-based vaccines in the era of personalized immunotherapy of cancer.Intratumoral Infection with Murine Cytomegalovirus Synergizes with PD-L1 Blockade to Clear Melanoma Lesions and Induce Long-term Immunity.Therapeutic Cancer Vaccines.Human Tumor Antigens and Cancer Immunotherapy.Trial Watch: DNA vaccines for cancer therapy.Antiproliferative effect of double suicide gene delivery mediated by polyamidoamine dendrimers in human Tenon's capsule fibroblasts.Current and emerging EGFR therapies for glioblastoma.The dawn of vaccines for cancer prevention.Local Immunotherapy of Cancer: Innovative Approaches to Harnessing Tumor-Specific Immune Responses.Targeted gene therapy of the HSV-TK/hIL-12 fusion gene controlled by the hSLPI gene promoter of human non-small cell lung cancer in vitro.
P2860
Q27021570-4A787704-049E-4952-AC2A-C49A32C3DFAEQ27021837-B9110ED6-54F7-4BFD-84EB-DA99D1CFCE92Q28083766-B23F6C89-F3B6-4F4B-ACB1-7726FFAE66C9Q28397609-831EB769-E54E-475F-BC3C-A05A018EDE4CQ30996881-05FE99A9-AED1-4AE6-9494-BE95BD350640Q33633839-6FAE57EF-FE2C-4E0D-A9CD-E2FAE663F42BQ34360094-F3D33D1C-CDFE-4C5D-A3FC-E29131D06DC9Q34452474-94E5003D-6B0E-42FA-8D94-28C4BFE72CE6Q35060537-42CA9DAC-B87F-439B-A622-92FC0C1808CEQ35186312-C45C845D-149B-4EEA-8207-A3E012686E59Q35213535-F67683F6-383B-4A5B-8030-68B7ECA59165Q35741852-CECE35FB-4276-4878-9232-1123F32F7BE3Q35798986-D9522A13-E6AE-4A02-AFD6-4FCF2C2207DCQ36113141-FCFE6971-0CBB-405A-B8DA-E6F42290E027Q36709157-E3B5673C-AC60-42FB-A7A5-869E0F2A0F07Q36845824-74340A81-B98D-4630-B9D1-F197069126B9Q37266006-7EC71AA8-C8FA-4411-891F-106ADD2940A5Q38040509-812DA1AE-82E5-460A-A2FE-E31220F7F666Q38156198-23BCB1C5-0AAE-4E49-9EBF-CB73749BE8B1Q38176419-E3FCE542-58AD-48E4-B48A-B3F5F2E59990Q38283918-FC89D883-124E-40EB-A801-CE39AF718BCFQ38293525-F2930D91-FD01-4BD6-A1B5-470BA5E7DA36Q38398877-8B604F39-EF6A-423E-AE99-7FE35A435CE6Q38407351-36117E0B-649E-4370-94BB-F007FDA779CEQ38539948-562876E3-1165-46E4-AE87-AC10CB4EAF92Q38660577-5AE72F9B-967E-470E-9A21-74DE8D69C680Q38828624-125934D4-9102-4DB2-A4F2-2E54CCCC3736Q38981383-61886664-D3E5-4C12-A08F-27A0B7009428Q39049093-92CF7B20-C620-486F-818C-424B27FC3FD1Q39327107-82023307-DB8E-4EA8-97E6-F60D8B1B4745Q40068135-C13930C4-DC11-411B-8C89-E936AA76E2BAQ40607907-B1E16A58-7660-42B3-AB1D-79AA52036FEDQ40728648-DA30DF1B-6C65-4DC0-9430-D92C2030F6C5Q41533232-A8CEF047-D69E-4F5C-AB73-CF80788FFC99Q42552005-BB3BFB85-C402-4723-A5A0-9F635B6656F7Q47114903-3F3866D2-F1E3-42D9-AA97-FAD04185695EQ47878958-0F452674-47CD-4E5B-9B84-CA2F57E7032AQ49566629-609D8CB7-2F88-4AE0-B90D-A4BD38665F32Q52353493-03E01B9D-C8AF-4996-B3F9-84AAD83EB46FQ54112053-01BB30B9-C686-481C-BBDC-8E5EBCBBC2AA
P2860
description
2011 nî lūn-bûn
@nan
2011 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Viral vector-based therapeutic cancer vaccines
@ast
Viral vector-based therapeutic cancer vaccines
@en
type
label
Viral vector-based therapeutic cancer vaccines
@ast
Viral vector-based therapeutic cancer vaccines
@en
prefLabel
Viral vector-based therapeutic cancer vaccines
@ast
Viral vector-based therapeutic cancer vaccines
@en
P2860
P1433
P1476
Viral vector-based therapeutic cancer vaccines
@en
P2093
Cecilia Larocca
Jeffrey Schlom
P2860
P304
P356
10.1097/PPO.0B013E3182325E63
P577
2011-09-01T00:00:00Z